LIVIVO - Search results -

Search results

Result 1 - 10 of total 316

Search options

Article: Assessment of Colistin Heteroresistance among Multidrug-Resistant

Braspenning, Anouk J M M / Rajakani, Sahaya Glingston / Sey, Adwoa / El Bounja, Mariem / Lammens, Christine / Glupczynski, Youri / Malhotra-Kumar, Surbhi

Antibiotics (Basel, Switzerland)

2024 Volume 13, Issue 3

Abstract: Heteroresistance (HR) to colistin is especially concerning in settings where multi-drug-resistant (MDR) ...

Abstract	Heteroresistance (HR) to colistin is especially concerning in settings where multi-drug-resistant (MDR)
Language	English
Publishing date	2024-03-20
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2681345-2
ISSN	2079-6382
ISSN	2079-6382
DOI	10.3390/antibiotics13030281
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article ; Online: Insight into Antibiotic Synergy Combinations for Eliminating Colistin Heteroresistant

Rajakani, Sahaya Glingston / Xavier, Basil Britto / Sey, Adwoa / Mariem, El Bounja / Lammens, Christine / Goossens, Herman / Glupczynski, Youri / Malhotra-Kumar, Surbhi

Genes

2023 Volume 14, Issue 7

Abstract: Colistin heteroresistance has been identified in several bacterial species, ... ...

Abstract	Colistin heteroresistance has been identified in several bacterial species, including
MeSH term(s)	Colistin/pharmacology ; Klebsiella pneumoniae/genetics ; Anti-Bacterial Agents/pharmacology ; Meropenem ; Tigecycline
Chemical Substances	Colistin (Z67X93HJG1) ; Anti-Bacterial Agents ; Meropenem (FV9J3JU8B1) ; Tigecycline (70JE2N95KR)
Language	English
Publishing date	2023-07-10
Publishing country	Switzerland
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2527218-4
ISSN	2073-4425 ; 2073-4425
ISSN (online)	2073-4425
ISSN	2073-4425
DOI	10.3390/genes14071426
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Emergence and dissemination of multi-resistant Gram negative Enterobacteriaceae: lessons to be learnt from local and national surveillance programs in Belgium.

Rodriguez-Villalobos, H / Glupczynski, Y

Acta clinica Belgica

2015 Volume 70, Issue 1, Page(s) 1–10

Abstract: Infections caused by multi drug resistant bacteria (MDRB) constitutes an international health care problem. Since the year 2000, a longitudinal surveillance programme (LSP) and two multicentric surveys (100 hospitals, 826 isolates) were performed to ... ...

Abstract	Infections caused by multi drug resistant bacteria (MDRB) constitutes an international health care problem. Since the year 2000, a longitudinal surveillance programme (LSP) and two multicentric surveys (100 hospitals, 826 isolates) were performed to monitor the emergence of MDRB in Belgium. The implementation of a LSP detected the emergence and spread of new types of ESBLs (CTX-M), mostly among community associated E. coli in the setting of a university hospital several years before the large spread and recognition in Belgium of a pathogenic E. coli CTX-M-15 (B2-O25:H4-ST131) pandemic clone (found in extra-intestinal virulent strains). This finding supports the progressive increase in Belgium of systemic infections including UTI caused by MDRB with limited therapeutical options. The real burden of the problem remains however, difficult to estimate in the absence of any surveillance network in Belgium to monitor the epidemiology of antimicrobial resistance in the community. The current Belgian national recommendations for the detection, surveillance, prevention and control of epidemics by ESBL-producing organisms and possibly other MDRBs (eg: Carbapenemase producing Enterobacteriaceae [CPE]) must be updated taking into accounts these new elements. A global coordinated network for antimicrobial surveillance resistance gathering experts (e.g: public health epidemiologists, representative of the national reference centres of antimicrobial resistance, field experts in infection control, infectious disease specialists, other clinicians and general practitioners) must be urgently implemented, including the longitudinal analysis of resistance in different ecosystems (human, animal, water and food).
MeSH term(s)	Animals ; Belgium ; Drug Resistance, Multiple, Bacterial/genetics ; Enterobacteriaceae/genetics ; Escherichia coli Proteins/genetics ; Humans ; Safety Management ; beta-Lactamases/genetics
Chemical Substances	Escherichia coli Proteins ; beta-Lactamases (EC 3.5.2.6) ; beta-lactamase CTX-M, E coli (EC 3.5.2.6)
Language	English
Publishing date	2015-02
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	390201-8
ISSN	2295-3337 ; 1784-3286 ; 0001-5512
ISSN (online)	2295-3337
ISSN	1784-3286 ; 0001-5512
DOI	10.1179/2295333714Y.0000000034
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.283: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Diversity in the Characteristics of

De Koster, Sien / Rodriguez Ruiz, Juan Pablo / Rajakani, Sahaya Glingston / Lammens, Christine / Glupczynski, Youri / Goossens, Herman / Xavier, Basil Britto

Frontiers in microbiology

2022 Volume 13, Page(s) 838207

Abstract: Background: Klebsiella pneumoniae: Materials and methods: We selected ten : Results: Hospital-associated : Conclusion: The study ... ...

Abstract	Background: Klebsiella pneumoniae Materials and methods: We selected ten Results: Hospital-associated Conclusion: The study of
Language	English
Publishing date	2022-02-10
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2587354-4
ISSN	1664-302X
ISSN	1664-302X
DOI	10.3389/fmicb.2022.838207
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: In vitro Activity of Cefiderocol and Comparators against Carbapenem-Resistant Gram-Negative Pathogens from France and Belgium.

Oueslati, Saoussen / Bogaerts, Pierre / Dortet, Laurent / Bernabeu, Sandrine / Ben Lakhal, Hend / Longshaw, Christopher / Glupczynski, Youri / Naas, Thierry

Antibiotics (Basel, Switzerland)

2022 Volume 11, Issue 10

Abstract: Infections with carbapenem-resistant (CR) Gram-negative (GN) pathogens have increased in many countries worldwide, leaving only few therapeutic options. Cefiderocol (CFDC) is approved in Europe for the treatment of aerobic GN infections in adults with ... ...

Abstract	Infections with carbapenem-resistant (CR) Gram-negative (GN) pathogens have increased in many countries worldwide, leaving only few therapeutic options. Cefiderocol (CFDC) is approved in Europe for the treatment of aerobic GN infections in adults with limited treatment options. This study evaluated the in vitro activity of cefiderocol and comparators against multidrug-resistant (MDR) bacteria including meropenem-resistant (MR) or pandrug-resistant (PR) GN clinical isolates from France and Belgium. The minimum inhibitory concentrations (MICs) of CFDC were determined by broth microdilution, using iron-depleted cation-adjusted Mueller-Hinton broth, and were compared to those of 10 last-line antibiotics. The MICs were interpreted according to EUCAST and CLSI breakpoints, and in the absence of species-specific breakpoints, non-species-related pharmacokinetic/pharmacodynamic breakpoints were used. Among the 476 isolates tested, 322 were carbapenemase producers (CP), 58 non-CP-CRs, 52 intrinsically CR, 41 expanded-spectrum cephalosporin resistant and 5 were multi-susceptible. Susceptibility to CFDC was high using EUCAST breakpoints 81%, 99% and 84%, and was even higher using CLSI breakpoints to 93%, 100% and 88% for Enterobacterales,
Language	English
Publishing date	2022-10-04
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2681345-2
ISSN	2079-6382
ISSN	2079-6382
DOI	10.3390/antibiotics11101352
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Evaluation of the RESIST-4 K-SeT assay, a multiplex immunochromatographic assay for the rapid detection of OXA-48-like, KPC, VIM and NDM carbapenemases.

Glupczynski, Youri / Evrard, Stéphanie / Huang, Te-Din / Bogaerts, Pierre

The Journal of antimicrobial chemotherapy

2019 Volume 74, Issue 5, Page(s) 1284–1287

Abstract: Objectives: Accurate and fast identification of carbapenemase producers is essential for optimal patient management. Here, a new lateral flow immunochromatographic RESIST-4 K-SeT assay was assessed for the detection of carbapenemases in ... ...

Abstract	Objectives: Accurate and fast identification of carbapenemase producers is essential for optimal patient management. Here, a new lateral flow immunochromatographic RESIST-4 K-SeT assay was assessed for the detection of carbapenemases in Enterobacteriaceae and non-fermenters. Methods: The RESIST-4 K-SeT assay targets OXA-48-like, KPC, VIM and NDM, but not IMP carbapenemases. The assay was first evaluated using a collection of isolates with well-characterized resistance mechanisms to β-lactams (n = 134) and against an international external quality assessment carbapenemase panel (n = 8). The assay was then challenged prospectively using 345 consecutive, non-duplicate isolates including 279 Enterobacteriaceae and 66 non-fermenters (mostly Pseudomonas spp.) that were sent to the Belgian National Reference Centre for identification of the mechanisms related to carbapenem resistance. Results: Globally, for the collection of retrospective and prospective clinical isolates (n = 479), the assay showed a sensitivity ranging from 99% for the detection of VIM to 100% for the detection of OXA-48-like, KPC and NDM carbapenemase-producing strains. The specificity was 100% for each carbapenemase and a perfect match in results was observed for the external quality assessment for the carbapenemases targeted by the assay. Conclusions: The RESIST-4 K-SeT assay is a valuable alternative for detection and identification of carbapenemases from culture isolates compared with the more costly molecular assays, which may also further require skilled staff and dedicated facilities.
MeSH term(s)	Chromatography, Affinity/methods ; Enterobacteriaceae/drug effects ; Enterobacteriaceae/genetics ; Enterobacteriaceae Infections/diagnosis ; Enterobacteriaceae Infections/microbiology ; Humans ; Retrospective Studies ; Sensitivity and Specificity ; beta-Lactam Resistance ; beta-Lactamases/genetics ; beta-Lactamases/metabolism
Chemical Substances	beta-Lactamases (EC 3.5.2.6)
Language	English
Publishing date	2019-02-11
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	191709-2
ISSN	1460-2091 ; 0305-7453
ISSN (online)	1460-2091
ISSN	0305-7453
DOI	10.1093/jac/dkz031
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1197: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 124: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: One Health surveillance of colistin-resistant Enterobacterales in Belgium and the Netherlands between 2017 and 2019.

De Koster, Sien / Xavier, Basil Britto / Lammens, Christine / Perales Selva, Natascha / van Kleef-van Koeveringe, Stefanie / Coenen, Samuel / Glupczynski, Youri / Leroux-Roels, Isabel / Dhaeze, Wouter / Hoebe, Christian J P A / Dewulf, Jeroen / Stegeman, Arjan / Kluytmans-Van den Bergh, Marjolein / Kluytmans, Jan / Goossens, Herman

PloS one

2024 Volume 19, Issue 2, Page(s) e0298096

Abstract: Background: Colistin serves as the last line of defense against multidrug resistant Gram-negative bacterial infections in both human and veterinary medicine. This study aimed to investigate the occurrence and spread of colistin-resistant ... ...

Abstract	Background: Colistin serves as the last line of defense against multidrug resistant Gram-negative bacterial infections in both human and veterinary medicine. This study aimed to investigate the occurrence and spread of colistin-resistant Enterobacterales (ColR-E) using a One Health approach in Belgium and in the Netherlands. Methods: In a transnational research project, a total of 998 hospitalized patients, 1430 long-term care facility (LTCF) residents, 947 children attending day care centres, 1597 pigs and 1691 broilers were sampled for the presence of ColR-E in 2017 and 2018, followed by a second round twelve months later for hospitalized patients and animals. Colistin treatment incidence in livestock farms was used to determine the association between colistin use and resistance. Selective cultures and colistin minimum inhibitory concentrations (MIC) were employed to identify ColR-E. A combination of short-read and long-read sequencing was utilized to investigate the molecular characteristics of 562 colistin-resistant isolates. Core genome multi-locus sequence typing (cgMLST) was applied to examine potential transmission events. Results: The presence of ColR-E was observed in all One Health sectors. In Dutch hospitalized patients, ColR-E proportions (11.3 and 11.8% in both measurements) were higher than in Belgian patients (4.4 and 7.9% in both measurements), while the occurrence of ColR-E in Belgian LTCF residents (10.2%) and children in day care centres (17.6%) was higher than in their Dutch counterparts (5.6% and 12.8%, respectively). Colistin use in pig farms was associated with the occurrence of colistin resistance. The percentage of pigs carrying ColR-E was 21.8 and 23.3% in Belgium and 14.6% and 8.9% in the Netherlands during both measurements. The proportion of broilers carrying ColR-E in the Netherlands (5.3 and 1.5%) was higher compared to Belgium (1.5 and 0.7%) in both measurements. mcr-harboring E. coli were detected in 17.4% (31/178) of the screened pigs from 7 Belgian pig farms. Concurrently, four human-related Enterobacter spp. isolates harbored mcr-9.1 and mcr-10 genes. The majority of colistin-resistant isolates (419/473, 88.6% E. coli; 126/166, 75.9% Klebsiella spp.; 50/75, 66.7% Enterobacter spp.) were susceptible to the critically important antibiotics (extended-spectrum cephalosporins, fluoroquinolones, carbapenems and aminoglycosides). Chromosomal colistin resistance mutations have been identified in globally prevalent high-risk clonal lineages, including E. coli ST131 (n = 17) and ST1193 (n = 4). Clonally related isolates were detected in different patients, healthy individuals and livestock animals of the same site suggesting local transmission. Clonal clustering of E. coli ST10 and K. pneumoniae ST45 was identified in different sites from both countries suggesting that these clones have the potential to spread colistin resistance through the human population or were acquired by exposure to a common (food) source. In pig farms, the continuous circulation of related isolates was observed over time. Inter-host transmission between humans and livestock animals was not detected. Conclusions: The findings of this study contribute to a broader understanding of ColR-E prevalence and the possible pathways of transmission, offering insights valuable to both academic research and public health policy development.
MeSH term(s)	Child ; Humans ; Animals ; Swine ; Colistin/pharmacology ; Colistin/therapeutic use ; Belgium/epidemiology ; Escherichia coli/genetics ; Netherlands/epidemiology ; Chickens/genetics ; Multilocus Sequence Typing ; One Health ; Anti-Bacterial Agents/pharmacology ; Anti-Bacterial Agents/therapeutic use ; Klebsiella pneumoniae ; Escherichia coli Proteins/genetics ; Microbial Sensitivity Tests ; Drug Resistance, Bacterial/genetics
Chemical Substances	Colistin (Z67X93HJG1) ; Anti-Bacterial Agents ; Escherichia coli Proteins
Language	English
Publishing date	2024-02-23
Publishing country	United States
Document type	Journal Article
ZDB-ID	2267670-3
ISSN	1932-6203 ; 1932-6203
ISSN (online)	1932-6203
ISSN	1932-6203
DOI	10.1371/journal.pone.0298096
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Structural and Biochemical Features of OXA-517: a Carbapenem and Expanded-Spectrum Cephalosporin Hydrolyzing OXA-48 Variant.

Dabos, Laura / Raczynska, Joanna E / Bogaerts, Pierre / Zavala, Agustin / Girlich, Delphine / Bonnin, Remy A / Dortet, Laurent / Peyrat, Aurélie / Retailleau, Pascal / Iorga, Bogdan I / Jaskólski, Mariusz / Glupczynski, Youri / Naas, Thierry

Antimicrobial agents and chemotherapy

2023 Volume 67, Issue 2, Page(s) e0109522

Abstract: OXA-48-producing Enterobacterales have now widely disseminated throughout the world. Several variants have now been reported, differing by just a few amino-acid substitutions or deletions, mostly in the region of the loop β5-β6. As OXA-48 hydrolyzes ... ...

Abstract	OXA-48-producing Enterobacterales have now widely disseminated throughout the world. Several variants have now been reported, differing by just a few amino-acid substitutions or deletions, mostly in the region of the loop β5-β6. As OXA-48 hydrolyzes carbapenems but lacks significant expanded-spectrum cephalosporin (ESC) hydrolytic activity, ESCs were suggested as a therapeutic option. Here, we have characterized OXA-517, a natural variant of OXA-48- with an Arg214Lys substitution and a deletion of Ile215 and Glu216 in the β5-β6 loop, capable of hydrolyzing at the same time ESC and carbapenems. MICs values of E. coli expressing
MeSH term(s)	Carbapenems/pharmacology ; Cephalosporins ; Escherichia coli/genetics ; beta-Lactamases/genetics ; beta-Lactamases/chemistry ; Ceftazidime ; Monobactams ; Anti-Bacterial Agents/pharmacology ; Microbial Sensitivity Tests
Chemical Substances	Carbapenems ; Cephalosporins ; beta-Lactamases (EC 3.5.2.6) ; Ceftazidime (9M416Z9QNR) ; Monobactams ; Anti-Bacterial Agents
Language	English
Publishing date	2023-01-17
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	217602-6
ISSN	1098-6596 ; 0066-4804
ISSN (online)	1098-6596
ISSN	0066-4804
DOI	10.1128/aac.01095-22
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 809: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Einzelsignatur: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Usefulness of bacteriological surveillance cultures for monitoring infection in hospitalized patients: a critical reappraisal.

Glupczynski, Y

Acta clinica Belgica

2001 Volume 56, Issue 1, Page(s) 38–45

Abstract: Untargeted bacteriological surveillance of superficial and deep body sites is frequently performed routinely in various clinical settings. This practice is based on the assumption that early identification of surface microbial flora might be predictive ... ...

Abstract	Untargeted bacteriological surveillance of superficial and deep body sites is frequently performed routinely in various clinical settings. This practice is based on the assumption that early identification of surface microbial flora might be predictive of organisms that will later cause invasive disease and that it may consequently assist in guiding empirical antibiotic therapy. A comprehensive review of the literature however indicates that the clinical value and cost-effectiveness of such practices still remain debated and appear largely unproven in most conditions and situations where they are routinely advocated. The present article reviews and critically discusses the available body of evidence supporting or disproving the use of bacteriological surveillance cultures. It is also aimed to issue general recommendations, strategies and methodologies that could be applied in different hospital care settings including the neonatal or adult intensive care as well as the hematology-oncology units.
MeSH term(s)	Belgium/epidemiology ; Colony Count, Microbial/economics ; Colony Count, Microbial/utilization ; Cost-Benefit Analysis ; Cross Infection/economics ; Cross Infection/prevention & control ; Humans ; Infection Control/methods ; Intensive Care Units/economics ; Intensive Care Units/statistics & numerical data ; Intensive Care Units, Neonatal/statistics & numerical data ; Population Surveillance ; Prospective Studies ; Sepsis/economics ; Sepsis/prevention & control
Language	English
Publishing date	2001-01
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	390201-8
ISSN	2295-3337 ; 1784-3286 ; 0001-5512
ISSN (online)	2295-3337
ISSN	1784-3286 ; 0001-5512
DOI	10.1179/acb.2001.007
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.283: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: COMBACTE LAB-Net: building a European laboratory network for clinical trials on anti-infectives.

Kostyanev, Tomislav / Timbermont, Leen / Vilken, Tuba / Lammens, Christine / Malhotra-Kumar, Surbhi / Glupczynski, Youri / Goossens, Herman

Future microbiology

2021 Volume 16, Page(s) 635–647

Abstract: LAB-Net, the laboratory network of COMBACTE, has established itself as an indispensable network for clinical trials in infectious diseases that plays a crucial part across 30 clinical studies not only within, but also outside the COMBACTE consortium. ... ...

Abstract	LAB-Net, the laboratory network of COMBACTE, has established itself as an indispensable network for clinical trials in infectious diseases that plays a crucial part across 30 clinical studies not only within, but also outside the COMBACTE consortium. Since its official launch in January 2013, LAB-Net has expanded more than threefold and in Q4 2020 it encompasses 841 labs across 41 countries in Europe. In addition, LAB-Net has crossed the European borders and collaborates with more than 300 laboratories spread across the globe. The tight collaboration with partners within COMBACTE and beyond contributed tremendously to the growth of LAB-Net over the years. A sustainable infrastructure beyond COMBACTE-NET is needed to ensure the smooth handover and continuity of the achievements made by the project.
MeSH term(s)	Anti-Infective Agents/therapeutic use ; Biological Specimen Banks ; Clinical Trials as Topic/organization & administration ; Clinical Trials as Topic/standards ; Clinical Trials as Topic/statistics & numerical data ; Data Collection ; Drug Development ; Europe ; Humans ; Laboratories/organization & administration ; Laboratories/standards ; Laboratories/statistics & numerical data ; Microbiological Techniques ; Quality Assurance, Health Care
Chemical Substances	Anti-Infective Agents
Language	English
Publishing date	2021-05-17
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2254620-0
ISSN	1746-0921 ; 1746-0913
ISSN (online)	1746-0921
ISSN	1746-0913
DOI	10.2217/fmb-2021-0096
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

Details ▾
- Full text online
- Order with fees

To top

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Order via subito